EpiCast Report: Chronic Obstructive Pulmonary Disease - Epidemiology Forecasts to 2025

Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty in breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by tobacco smoking; however, long-term exposure to other lung irritants, such as smoke from vehicle emissions and power stations, chemical fumes, and dust from the environment and workplace, can also contribute to the development of COPD (NHLBI, 2013).

To forecast the total prevalent cases of COPD and the diagnosed prevalent cases of COPD in the 8MM, GlobalData epidemiologists used studies published in peer-reviewed journals that provided the age- and sex-specific total and diagnosed prevalent cases of COPD in the respective markets. The forecast methodology was consistent across the 8MM to allow for a meaningful comparison of the forecast numbers across the markets.

In the 8MM, GlobalData epidemiologists forecast that the total prevalent cases of COPD will increase from 65,991,432 cases in 2015 to 76,066,482 cases in 2025 at an Annual Growth Rate (AGR) of 1.53%. In the 8MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of COPD will increase from 24,482,101 cases in 2015 to 27,924,212 cases in 2025 at an AGR of 1.41%. The US had the highest number of total and diagnosed prevalent cases of COPD in the 8MM.

Scope

The Chronic obstructive pulmonary disease (COPD) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of COPD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the total prevalent cases of COPD (diagnosed and undiagnosed cases) and the diagnosed prevalent cases of COPD, which are segmented by sex and age (35–44, 45–54, 55–64, 65–74, and 75 years and older). The diagnosed prevalent cases of COPD are further segmented by the new GOLD 2011 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.

The COPD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The COPD EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global COPD market.

Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.

Understand severity stages of COPD cases by CAT score and mMRC scores.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Chronic Obstructive Pulmonary Disease: Executive Summary

2.1 Related Reports ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Chronic Obstructive Pulmonary Disease: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Total Prevalent Cases

3.4.4 Diagnosed Prevalent Cases

3.4.5 Diagnosed Prevalent Cases of COPD by Severity

3.5 Epidemiological Forecast for COPD (2015-2025)

3.5.1 Total Prevalent Cases of COPD

3.5.2 Age-Specific Total Prevalent Cases of COPD

3.5.3 Sex-Specific Total Prevalent Cases of COPD

3.5.4 Diagnosed Prevalent Cases of COPD

3.5.5 Age-Specific Diagnosed Prevalent Cases of COPD

3.5.6 Sex-Specific Diagnosed Prevalent Cases of COPD

3.5.7 Diagnosed Prevalent Cases of COPD by Severity

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of Analysis

3.6.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: Risk Factors and Comorbidities for COPD

Table 2: New GOLD 2011 Criteria for COPD Severity Stages

Table 3: 8MM, Total Prevalent Cases of ...

Table 1: Risk Factors and Comorbidities for COPD

Table 2: New GOLD 2011 Criteria for COPD Severity Stages

Table 3: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years 2015–2025

Table 4: 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2015.

Table 5: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years 2015–2025

Table 6: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N, 2015

List of Figures

Figure 1: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, 2015 and 2025

Figure 2: 8MM, Diagnosed Prevalent Cases of COPD, Both ...

Figure 1: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, 2015 and 2025

Figure 2: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, 2015 and 2025

Figure 3: 8MM, Age-Standardized Total Prevalence of COPD (%), Ages ≥35 Years, 2015

Figure 4: 8MM, Age-Standardized Diagnosed Prevalence of COPD (%), Ages ≥35 Years, 2015

Figure 5: 8MM, Sources Used and Not Used to Forecast Total Prevalent Cases of COPD

Figure 6: 8MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of COPD

Figure 7: 8MM, Sources Used to Forecast the new GOLD 2011 Severity Stages Among the Diagnosed Prevalent Cases of COPD

Figure 8 : 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2015

Figure 9: 8MM, Sex-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2015

Figure 10: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N, 2015

Figure 11: 8MM, Sex-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N, 2015

Figure 12: 8MM, Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage (Using mMRC), Both Sexes, 2015

Figure 13: 8MM, Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage (Using CAT), Both Sexes, 2015

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports